BioCryst Pharmaceuticals’ (BCRX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $30.00 price target on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. Needham & Company LLC increased their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Barclays increased their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Evercore ISI boosted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Stock Up 1.3 %

Shares of BCRX stock opened at $8.47 on Tuesday. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $9.50. The company’s fifty day simple moving average is $8.09 and its 200-day simple moving average is $7.85. The firm has a market cap of $1.75 billion, a PE ratio of -13.89 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. BioCryst Pharmaceuticals’s quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.28 earnings per share. On average, equities analysts predict that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $33,000. Venturi Wealth Management LLC acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter worth approximately $46,000. R Squared Ltd bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $48,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,322 shares during the period. Finally, KBC Group NV increased its stake in shares of BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.